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ABSTRACT: Myeloid cells play a central role in the context of viral
eradication, yet precisely how these cells diﬀerentiate throughout the
course of acute infections is poorly understood. In this study, we have
developed a novel quantitative temporal in vivo proteomics (QTiPs)
platform to capture proteomic signatures of temporally transitioning
virus-driven myeloid cells directly in situ, thus taking into considera-
tion host−virus interactions throughout the course of an infection.
QTiPs, in combination with phenotypic, functional, and metabolic
analyses, elucidated a pivotal role for inﬂammatory CD11b+, Ly6G−,
Ly6Chigh‑low cells in antiviral immune response and viral clearance.
Most importantly, the time-resolved QTiPs data set showed the
transition of CD11b+, Ly6G−, Ly6Chigh‑low cells into M2-like macrophages, which displayed increased antigen-presentation
capacities and bioenergetic demands late in infection. We elucidated the pivotal role of myeloid cells in virus clearance and show
how these cells phenotypically, functionally, and metabolically undergo a timely transition from inﬂammatory to M2-like
macrophages in vivo. With respect to the growing appreciation for in vivo examination of viral−host interactions and for the role
of myeloid cells, this study elucidates the use of quantitative proteomics to reveal the role and response of distinct immune cell
populations throughout the course of virus infection.
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■ INTRODUCTION
Myeloid immune cell populations are phenotypically dynamic
and arise from a common pluripotent hematopoietic stem cell
lineage. Following infection, bone marrow (BM)-emigrating
immature monocytic myeloid cellsidentiﬁed in mice as
CD11b+, Ly6G−, Ly6C+ cellsare recruited to the site of infec-
tion and mediate antimicrobial, as well as inﬂammatory, func-
tions. Importantly, site-speciﬁc environmental cues dictate the
functionality and cellular phenotype of these myeloid cells,
ranging from pro-inﬂammatory to immunosuppressive. It is
hypothesized that, through a temporal transition, these inﬂam-
matory immature myeloid cells diﬀerentiate into monocytes and
macrophages that acquire speciﬁc phenotypes, functionalities,
and metabolic proﬁles throughout infection. Such plasticity per-
mits these myeloid cells to be associated with a plethora of
pathological conditions including pathogenic infections,1−3
inﬂammatory diseases/responses,4,5 cancer progression,6−9 and
antitumor immune responses.10
Following infection, recruitment and transition of inﬂamma-
tory CD11b+, Ly6C+ cells are instrumental in L. monocytogenes,2
K. pneumoniae,1 and inﬂuenza virus clearance.11 Although the
exact mechanism of how inﬂammatory CD11b+, Ly6G−, Ly6C+
cells contribute to pathogenic clearance is unclear, it is apparent
that these cells are pivotal in both innate immunity as well as
adaptive immunity.1,12 Thus, an in depth examination of their
transitory, temporal, and stage-speciﬁc phenotype is necessary to
understand the role and function of virus-driven inﬂammatory
myeloid cells.
Changes in immune cell functions during infections are depen-
dent on dynamic proteomic changes over time. Notwithstanding
previous technological challenges, comprehensive and tempo-
ral characterization of proteomes to understand cellular func-
tion is now possible due to recent advancements in multiplex
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quantitative proteomics.13,14 Combined with novel synchronous
precursor selection with three-stage mass spectrometry (SPS-
MS3) acquisition methods, extremely precise measurements of
cellular proteomes are now possible.15,16 Although proteomic
analysis has previously captured single time point “snapshots” of
in vivo cell populations, in vivo dynamics of immune cell popula-
tions have not been explored. Here, we report a quantitative
temporal in vivo proteomics (QTiPs) approach, which combines
SPS-MS3-based 10-plex quantitative proteomics with ﬂow
cytometry-based cell sorting to precisely capture temporospatial
proteomic changes of newly recruited, transitory CD11b+,
Ly6G−, Ly6Chigh‑low cells during reovirus infection.
Reovirus is a benign, enteric, human dsRNA virus that drives
an acute viral infection and is readily cleared through an immuno-
competent host.17 In addition to its use as a model of acute
infection, reovirus is known for its potent preferential cancer-
killing (also known as oncolytic) activities and is being tested as a
therapeutic oncolytic virus in phase I, II, and III clinical trials
internationally for the treatment of a variety of tumors.18−23
In this context, it is now clear that immunological events initiated
following the administration of reovirus in immunocompetent
hosts are the indispensable part of reovirus-based cancer therapy.
Thus, the detailed understanding of immunological events
initiated following viral infection is pertinent to the therapeutic
eﬀectiveness of oncolytic virus-based cancer immunother-
apy.24,25 Thus, using QTiPs combined with phenotypic, tran-
scriptional, functional, and metabolic validations, we illustrate a
temporal transition of reovirus-driven CD11b+, Ly6G−, Ly6C+
cells from their role in innate antiviral immune response
(CD11b+, Ly6G−, Ly6Chigh cells) to their acquisition of
M2-like macrophage phenotype (CD11b+, Ly6G−, Ly6Clow cells)
during viral infection. Our QTiPs approach reports a novel
platform to elucidate in depth, quantitative, temporospatial cel-
lular transitions in the context of various pathophysiological
conditions in situ. Our QTiPs approach reports a novel platform
to elucidate in depth, quantitative, temporospatial cellular transi-
tions in the context of various pathophysiological conditions
in situ.
■ EXPERIMENTAL SECTION
Antibodies and Reagents
The following reagents used were purchased from Biolegend
(San Diego, CA): FITC-antimouse Ly6G (1A8), Alexa Fluor
647-antimouse Ly6G (1A8), PE-antimouse Ly6C (Hk1.1),
APC-antimouse Ly6C (Hk1.1), Alexa Fluor 647-antimouse
CD206 (C068C2), PerCP/Cy5.5-antimouse CD11b (M1/70),
Alexa Fluor 647-antimouse MHC-11 (I-A/I-E) (M5/114.15.2),
and PE-antimouse H.2kb bound to SIINFEKL (25-D1.16).
Antimouse CD16/32 (93) and APC-antimouse CCR2 (cat#
FAB5538a) were purchased from BioXCell (West Lebanon,
NH) and R&D Systems (Minneapolis, MN), respectively.
Metabolic stains, DAF-FM diacetate (4-amino-5-methylamino-
2′,7′-diﬂuoroﬂuorescein diacetate) (D23844), andCM-H2DCFDA
(C6827) were purchased from Molecular Probes (Thermo-
Fisher Scientiﬁc, Rochford, IL, USA).
Ethics Statement
In vivo experimental procedures were approved by the Dalhousie
University Animal Ethics Committee in accordance with the
regulations/guidelines from the Canadian Council on Animal
Care (CCAC) (project numbers 14-086 and 16-107). C57BL/6
mice were purchased from Charles River Laboratory (Montreal,
Quebec, Canada), and CCR2KO and C57BL/6-GFP mice were
purchased from Jackson Laboratory (Bar Harbor, ME).
QTiPs Sample Preparation and Analysis
Animals were injected with reovirus as previously described,26,27
and inﬂammatory myeloid cells were collected from the site of
infection as well as bone marrow on 1, 3, 5, 7, and 10 days post-
infection (d.p.i.). Harvested cells were collected and stained as
previously described26 and sorted using a FACSAria III (BD
Biosciences), resulting in ∼95% purity. Isolated cells were
washed with PBS, pelleted, and lysed in 6 M guanidine-HCl,
50 mM HEPES, pH 8.5, containing Roche complete mini
protease inhibitor mixture (1 tablet per 10 mL) (Roche,
Madison, WI). Lysis was performed via sonication and cleared
by centrifugation. Cysteine residues were reduced using 5 mM
dithiothreitol and then alkylated with 14 mM iodoacetamide.
Aliquots containing 50 μg of protein were diluted to 1.5 M
guanidine-HCl, 50 mM HEPES (pH 8.5) and digested with
trypsin (Promega, Madison, WI). Digested peptides were
desalted using 60 mg solid-phase C18-extraction cartridges
(Waters, Milford, MA), lyophilized, and labeled using TMT
10-plex reagents as described previously.28 Samples were then
mixed equally, desalted using solid-phase C18 extraction car-
tridges (Waters, Milford, MA), and lyophilized.
TMT10-labeled samples were fractionated using high-pH
reversed phase chromatography performed with an Onyx
monolithic 100 × 4.6 mm C18 column (Phenomenex, Torrance,
CA). The ﬂow rate was 800 μL/min, and a gradient of 5−40%
acetonitrile (10mM ammonium formate, pH 8) was applied over
60 min using an Agilent 1100 pump (Agilent) from which 12
fractions were collected. Fractions were desalted using home-
made Stage Tips,29 lyophilized, and analyzed with an Orbitrap
Fusion mass spectrometer (Thermo-Fisher Scientiﬁc, Rochford,
IL) using the SPS-MS3 method as described previously.28,29
Protein identiﬁcation was performed using a database search
against a mouse proteome database (downloaded fromUniProtKB
in September 2014) concatenated to a mammalian orthoreovirus
3 (Dearing strain) database (downloaded from UniProtKB in
September 2014). All false discovery rate (FDR) ﬁltering and
protein quantitation was performed as previously described.28
A protein was required to have a minimum total signal-to-noise
of 100 in all TMT reporter channels, and the maximum number
of missing channels was equal to 8. Data for heat maps and
individual protein proﬁles are represented by relative intensity,
which is based on the summed signal-to-noise.
GO-annotation analysis was originally conducted on the whole
data set using the open access Gene Ontology Consortium.30,31
The data set was subsequently analyzed via k-means clustering
with Euclidean distance using MultiExperiment Viewer (MeV)32
followed by DAVID Bioinformatics Resources (https://david.
ncifcrf.gov/) to conduct GO-term analysis for BPs, MFs, and
cellular compartments on speciﬁc clusters. Our total data set
was utilized as the background for the data analysis searches. For
the indicated experiments, the Interferome Web site33 and
MitoCarta database34,35 were utilized to cross-list for proteins
associated with interferon (IFN) response and mitochondrial-
associated proteins, respectively. Insertion of individual clusters
into the Interferome search engine identiﬁed IFN-associated
proteins and classiﬁed such proteins into diﬀerent IFN
types. The mass spectrometry proteomics data (Data S-1) have
been deposited into ProteomeXchange Consortium36 via the
PRIDE37 partner repository with the data set identiﬁer
PXD005064.
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Figure 1. QTiPs analysis of CD11b+, Ly6G−, Ly6Chigh‑low cells following reovirus infection. (A) Schematic representation of the ﬂow-through for the
temporospatial proteomic approach combining ﬂuorescence-activated cell sorting with TMT-mass spectrometry-based proteomics throughout viral
infection (intraperitoneal injection [i.p.]). Dot plots represent the gating strategy and isolated population (CD11b+, Ly6G−, Ly6Chigh‑low cells conserved
within the black box) from each collection point from the SOI and BM. A pooled population of CD11b+, Ly6G−, Ly6Chigh‑low myeloid cells were isolated
from 10 C57BL/6 mice at 1, 3, 5, 7, and 10 d.p.i. (B) Relative intensity of total quantitative proteomic analysis of CD11b+, Ly6G−, Ly6Chigh‑low cells
throughout infection in both the SOI and BM. (C) Comparing 10 to 1 d.p.i. SOI- and BM-isolated cells. (D) GO term enrichment analysis of the
biological process terms of total proteomic analysis. (E) Representative protein intensity proﬁles of selective targets from the highlighted biological
process terms (cellular process, immune system process, and metabolic process).
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Flow Cytometry and Analysis
Flow cytometry of harvested all immune cells from the spleen
and bone marrow from independently collected animals as
previously described.26 Peritoneal cavity (PC) cells were
harvested via a ﬂush of the PC with PBS. Flow cytometry for
MHC-ova (SIINFEKL) was conducted by ﬁrst pulsing unlabeled
immune cells harvested from the PC with SIINFEKL peptide
(5 μg/mL) for 2 h at 37 °C in RPMI complete media (5% vol/vol
Glutamax, 10% fetal bovine serum [FBS], 1× sodium pyruvate,
1× nonessential amino acids, and 1× Anti-Anti [Invitrogen,
Carlsbad, CA]). Harvested cells (PC, spleen, and BM) were
treated with RBC-lysing ammonium chloride (ACK) buﬀer,
washed, and blocked with anti-CD16/32 antibody prior to
primary antibody. For metabolic stains (NO and ROS), cells
were incubated with 2.5 μM DAF-FM diacetate (4-amino-5-
methylamino-2′,7′-diﬂuoroﬂuorescein diacetate) (D23844;Molec-
ular Probes) or 2.5 μM CM-H2DCFDA (C6827; Molecular
Probes) for 30 min at 37 °C in combination with antibodies in
ﬂow cytometry running buﬀer (PBS-EDTA with 1% FBS)
(FACS buﬀer). Cells harvested for ﬂow cytometry, with the
exception of DAF-FM- or DCF-stained cells, were ﬁxed with 4%
PFA, washed, and resuspended in FACS buﬀer prior to analysis.
Flow cytometry data were collected using a FACSCalibur ﬂow
cytometer (BD Bioscience), and analysis was conducted with
the use of CellQuest Pro (BD Bioscience) and FCS Express V3
software (DeNovo Software, Los Angeles, CA).
Reovirus Production and Plaque Assays
Reovirus (serotype 3, Dearing strain) was cultured, ampliﬁed,
and isolated using a previously established protocol.38 Reovirus
was titered on L929 cells (American Type Culture Collection,
Manassas, VA) by standard plaque assay as described pre-
viously.27,39 L929 cells were cultured in minimum essential
media with 5% vol/vol Glutamax, 5% fetal bovine serum, 1×
sodium pyruvate, 1× nonessential amino acids, and 1× Anti-Anti
(Invitrogen, Carlsbad, CA). To assess the intra- and extracellular
virus from the (site of infection) SOI, 5 mL of PBS was added to
the peritoneal cavity. The resultant peritoneal ﬂush was collected
and spun down at 500g for 6min to separate the cells (for analysis
of intracellular virus) from the extracellular fraction (contain-
ing the free extracellular virus). Either sorted CD11b+, Ly6G−,
Ly6Chigh‑low cells or nonsorted cells (total heterogeneous popula-
tion of cells) from such a peritoneal ﬂush were lysed with RIPA
buﬀer (0.05 M Tris-HCl, pH 7.4, 0.15 M NaCl, 0.25% deoxy-
cholic acid, 1% NP-40, 1 mM EDTA) to extract intracellular
virus. To determine the viral titer (plaque forming units/mL),
L929 cells were infected with a serial dilution of cell lysate or
peritoneal ﬂush supernatant. Virus titers were accessed 96 h post
the initial L929 cell infection.
Quantitative Real-Time PCR
RNA extractions, cDNA synthesis, and qPCR were conducted as
previously described26 on independently collected samples. The
indicated gene-speciﬁc primers were purchased from Invitrogen.
Data were analyzed using Livak and Schmittgen’s 2−ΔΔCT
method40 and normalized to Gapdh.
Extracellular Flux Analysis and Calculations
Sorted cells (5 × 105 cells), independently collected from a
pooled population of 5−10 mice, were resuspended in XF media
and plated onto X24 Seahorse cell plates coated with Cell-Tak
(Corning). Oxygen consumption rate (OCR) and extracellular
acidiﬁcation rate (ECAR) were measured in XF assay media
under basal conditions and in response to 1 μM oligomycin,
1.5 μMcarbonyl cyanide 4-(triﬂuoromethoxy)-phenylhydrazone
(FCCP), 1 μM rotenone, and 1 μM antimycin A (all purchased
from Sigma-Aldrich, ON, Canada) on the XF24 extracellular ﬂux
analyzer (Seahorse Bioscience, Billerica, MA, USA). Basal OCR
was calculated by subtraction of the residual rate after antimycin A
treatment. Maximal rate was calculated by subtraction of the
residual rate after antimycin A treatment from FCCP-induced
OCR. Proton leak was calculated as the diﬀerence between OCR
after oligomycin treatment and OCR after antimycin A treat-
ment. ATP production was calculated by subtraction of OCR
after oligomycin treatment from basal OCR. Spare respiratory
capacity was calculated by the diﬀerence between maximal OCR
and basal OCR. Spare respiratory capacity coupling eﬃciency
was calculated by the dividend of basal OCR and ATP pro-
duction. Glycolytic capacity was calculated as the ECAR after
oligomycin treatment. Glycolytic reserve was calculated by the
diﬀerence between glycolytic capacity and ECAR. Glycolytic
reserve percentage was calculated by the dividend of glycolytic
capacity and ECAR.
M1- and M2-like Macrophage Generation/Diﬀerentiation
Bone marrow cells were collected from femur and tibia bones
and cultured for 6−8 days in RPMI complete media supple-
mented with granulocyte macrophage colony-stimulating factor
(20 ng/mL for M1-like macrophages) or macrophage colony-
stimulating factor (100 ng/mL for M2-like macrophages).
Statistical Analysis
Depending on the indicated experiment, one-way ANOVA with
Bonferroni post-test or a two-tailed Student’s t-test with 95%
conﬁdence interval were used for statistical analysis, and p values
of <0.05 were considered signiﬁcant. Asterisks were used to
signify p values as not signiﬁcant (ns) = p > 0.05, *p ≤ 0.05, **p
≤ 0.01, and ***p ≤ 0.001.
■ RESULTS
QTiPs of Virus-Induced CD11b+, Ly6G−, Ly6Chigh Myeloid
Cells
Exposure to pathogens, especially viruses, drives the recruitment
of CD11b+, Ly6G−, Ly6Chigh myeloid cells that undergo
functional transition at the site of infection. To directly visualize
this transition of newly recruited, virus-induced myeloid cells
in situ, we performed 10-plex quantitative mass spectrometry
(MS) on temporally collected, cell-sorted, reovirus-drivenmyeloid
cells. Reovirus induces the accumulation of otherwise absent
CD11b+, Ly6G−, Ly6Chigh cells at the site of infection as early
as 1 d.p.i., which subsequently exhibited a gradual loss of Ly6C
expression over time (hence the reference to these cells as
CD11b+, Ly6G−, Ly6Chigh‑low; Figure 1A and Figure S-1A-B).
These CD11b+, Ly6G−, Ly6Chigh‑low cells were sorted from the
site of infection (SOI, inﬂammatory) and the BM (resident)
from 10 C57BL/6 mice per collection point. QTiPs analysis
identiﬁed 6634 proteins and quantiﬁed 5019 proteins from the
in vivo harvested and cell-sorted myeloid cell population span-
ning the course of 10 days in both the SOI and BM (Figure 1B,
Data S-1). Comparing 10 to 1 d.p.i., SOI-isolated cells contained
more proteomic changes (>- or <2-fold) than in the BMmyeloid
cells (12.69 vs 5.46%, respectively) (Figure 1C). Because the
QTiPs data set provides rich temporal proteomic data, it can be
interrogated further to reveal temporally distinct virus-driven
myeloid cell changes over the course of acute infection.
Because of the limited knowledge of the overall proteomic sig-
nature of CD11b+, Ly6G−, Ly6Chigh‑low cells, we ﬁrst conducted
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GO annotation analysis30,31 of all identiﬁed proteins in our data
set. The most represented biological processes (BPs) were cel-
lular (including cell cycle, proliferation, recognition, and growth)
and metabolic (including catabolic, biosynthetic, and coenzyme)
processes pertaining to 33.6 and 20.7% of the overall annotation
analysis, respectively (Figure 1D and Figure S-1C). As antic-
ipated, we observed immune system-associated BPs (Figure 1D),
which encompassed antigen processing/presentation, immune
response, and macrophage activation BPs (Figure S-1C). Inves-
tigation of BP-associated proteins identiﬁed temporal diﬀerences
between the SOI and BM. For example, immune-associated pro-
teins (complement C4-B, IFN-inducible GTPase 1, and activated
macrophage/microglia WAP domain protein [WFDC17]) were
predominantly higher in the SOI-isolated cells. Interestingly,
unlike complement C4-B and IFN-inducible GTPase, which
peak in relative abundance at 1 and 5 d.p.i., respectively. WFDC17
increased ∼10-fold from 1 to 10 d.p.i., suggesting a time-
dependent discrepancy in immune function (Figure 1E). Addi-
tionally, numerous cell cycle-associated proteins (e.g., Retino-
blastoma-like protein 1) were more abundant in BM-isolated
fractions, proposing that cellular proliferation of these myeloid
cells is greater in the BM. Because metabolic alterations can
contribute to immune cell function/diﬀerentiation, we inspected
the data set for metabolic proteins and observed a 2.1- and
8.4-fold induction of lactate dehydrogenase and glutamine syn-
thetase, respectively, from 1 to 10 d.p.i. in SOI-isolated cells;
however, no change was observed within the BM-isolated
collections (Figure 1E). These changes suggest that SOI-isolated
cells develop a more Warburg-like metabolism at 7 and 10 d.p.i..
Collectively, our QTiPs approach successfully captured tempo-
ral, quantitative, and spatially comparable proteomes of transi-
tory myeloid cells directly from their in situ microenvironment.
Temporal Transition of Inﬂammatory CD11b+, Ly6G−,
Ly6Chigh Cells Aids in Viral Clearance
To understand distinct functions of virus-driven CD11b+, Ly6G−,
Ly6Chigh cells, we clustered the data set using k-means clustering,
revealing temporally distinct patterns of protein expression. Three
of ten clusters contained proteins repressed over the period of
1−10 d.p.i. (Figure S-2). GO annotation analysis using DAVID
bioinformatics41,42 of cluster #1 (decreased expression patterns
Figure 2. CD11b+, Ly6G−, Ly6C+ cells mount an antiviral immune response early following reovirus infection. Clusters #1−3 were generated via
k-means cluster analyses using the Euclidean distance metric and are representative of three of ten clusters of the total proteomic analysis. GO
annotation analysis of biological process (BP) andmolecular function (MF) for clusters #1 (A, B), #2 (C, D), and #3 (E, F) using DAVID bioinformatics
are summarized in a bar graph and are represented as individual protein proﬁles for the indicated GO terms. Bar graphs illustrate the −log10 (adjusted
[adj.] p-value) and number of identiﬁed targets per GO term (in brackets). These data are representative of a pooled cell-sorted population from
10 C57BL/6 mice per collection time point.
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from 1 to 3 d.p.i.) showed an over-representation of BPs cor-
responding to response to cytokine stimulus, humoral immune
response, defense response (e.g., IFIH1 and CCL2), and steroid
metabolic processes (Figure 2A, B). Alongside these BPs, serine-
type peptidase and endopeptidase inhibitor activity molecu-
lar functions (MFs) were over-represented within this cluster
Figure 3. Reovirus-driven CD11b+, Ly6G−, Ly6Chigh cells display a predominant type I IFN response during the early stages of infection. Individual
protein proﬁles of selective IFN-associated proteins of cluster #1 (A), #2 (B), and #3 (C) using an Interferome database of annotated IFN-associated
proteins. (D) qRT-PCR validation of the indicated genes on isolated CD11b+, Ly6G−, Ly6Chigh‑low cells. Bars are the representative mean of n = 2 of
pooled populations of 5−10 mice per collection time point for both SOI- and BM-isolated cells, ran in duplicate and normalized to GAPDH, and
compared to 1 d.p.i. BM sample to obtain the fold change. (E) Interferome database of annotated IFN-associated genes from clusters #1−3 were
represented in Venn diagram categorized with respect to type I−III IFN.
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Figure 4. Reovirus-driven, CCR2-dependent recruitment/accumulation of CD11b+, Ly6G−, Ly6Chigh‑low cells hinder viral persistence. (A) Proteomic
identiﬁcation and temporospatial quantitation of reovirus (lambda-2) protein. Temporal reovirus titers from intracellular reovirus (B) in isolated
CD11b+, Ly6G−, Ly6Chigh‑low cells (pfu/1 × 106 cells) and extracellular reovirus (C) collected from the SOI of reovirus infected animals at the d.p.i.
(D) Flow cytometry analysis of CD11b+, Ly6G−, Ly6Chigh‑low cell frequency/kinetics from the SOI of wild-type C57BL/6 and CCR2KO mice.
(E) Intracellular reovirus titers (pfu/1 × 106 immune cells) collected from the SOI of wild-type C57BL/6 and CCR2KO mice at the indicated time
points post-injection. (F) Intracellular staining of ROS (DCF) andNO (DAF-FM) of CD11b+, Ly6G−, Ly6Chigh‑low cells and shown as mean ﬂuorescent
intensity (M.F.I.). Graphs in B, C, E, and F are representative of mean ± SEM with n = 5−6 mice per collection. The graph in D is mean ± SEM and
representative of n = 30 wild-type C57BL/6 mice and n = 3−8 CCR2KO mice per collection point post-injection. One-way ANOVA with Bonferroni
post-test (B−D and F) or two-tailed Student’s t-test (E) with 95% conﬁdence interval were used for statistical analysis, and p-values of <0.05 were
considered signiﬁcant. Asterisks were used to signify p-values as *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
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(e.g., ZP1 and HRG). In cluster #2 (expression peak at 5 d.p.i.),
we observed an over-representation of response to wounding,
response to stimulus (hormone and positive regulation) (e.g.,
CCL7 and CCL12), and endopeptidase inhibitor activity (e.g.,
SPA3K and MUG1) (Figure 2C, D). These data suggest that
SOI-isolated cells are early responders to viral infection. Further-
more, cluster #3 represented proteins with a general elevated
relative intensity within SOI- vs BM-isolated cells. GO annotation
of cluster #3 showed an over-representation of BP-associated
categories for the response to virus (e.g., RSAD2 and toll-like
receptor 3 [TLR3]), response to wounding, endocytosis, and
antigen processing/presentation (e.g., ICAM1 and HA11)
(Figure 2E, F). Speciﬁcally, cluster #3 contained hallmark viral
infection-associated immunological targets, such as 2′-5′-oligoade-
nylate synthase 1A (OAS1A), TLR3, TLR9, H-2 Class-I histocom-
patibility antigen, β-2-microglobulin, and ICAM1. Collectively, this
Figure 5. Reovirus-driven CD11b+, Ly6G−, Ly6Chigh‑low cells acquire increased antigen processing/presentation properties at later stages of infection.
(A) K-means cluster analyses with Euclidean distance represented by relative intensity heat map of cluster #4 (1 of 10 clusters) of the total proteomic
analysis of CD11b+, Ly6G−, Ly6Chigh‑low cells (illustrated in Figure 1B). (B) GO annotation analysis of BP and MF for cluster #4 using DAVID
bioinformatics, summarized in bar graph, illustrating the −log10 (adjusted [adj.] p-value), and number of identiﬁed targets per GO term (in brackets).
(C, D) Individual protein proﬁles of the indicatedMF and BP, respectively. Flow cytometry analysis of theMHC class II (E) andMHC class I-OVA (F)
surface expression (represented in M.F.I.) of CD11b+, Ly6G−, Ly6Chigh‑low myeloid cells throughout the course of infection. Ova peptide (SIINFEKL)
pulsed CD11b+, Ly6G−, Ly6Chigh‑low myeloid cells were analyzed for MHC class I-OVA (mean ﬂuorescent intensity, M.F.I.) at the indicated collections
post. These experiments (E, F) are representative bar graphs of mean ± SEM with n = 3−5. One-way ANOVA with Bonferroni post-test (E, F) with a
95% conﬁdence interval were used for statistical analysis, and p-values of <0.05 were considered signiﬁcant. Asterisks were used to signify p-values as
*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
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analysis reveals a time-dependent transition of inﬂammatory
CD11b+, Ly6G−, Ly6Chigh‑low cells and suggests a role for inﬂam-
matory CD11b+, Ly6G−, Ly6Chigh‑low cells in antiviral immunity.
Considering that reovirus exposure stimulates pattern recog-
nition receptors (PRRs), especially toll-like receptor 3 (TLR-3),
and produces a type I IFN response, clusters #1−3 were
additionally analyzed using an Interferome database.33 This anal-
ysis revealed proﬁles for numerous IFN-associated genes (e.g.,
ISG20, MPEG1, IFI5A, Q9DCE9, and IRG1) (Figure 3A−C).
Gene-speciﬁc RT-PCR ampliﬁcation of Isg56, Cd40, Igtp,
Serpina3k,Ccl7, If it3, Irgm1,Trafd1, and If i5a showed compatible
mRNA expression trends with that of their respective protein
expression proﬁles from clusters #1−3 (Figure 3D). Importantly,
temporal changes in IFN-associated protein expression were
mostly within SOI-isolated cells as opposed to their BM-isolated
counterparts. Categorizing these IFN-associated proteins into
type I and II responses emphasizes a predominant type I
IFN-response from SOI-isolated cells early following infection
in addition to a secondary elevation in type II IFN-associated
proteins (shown in cluster #2) (Figure 3E). Together, these
results suggest that CD11b+, Ly6G−, Ly6Chigh‑low cells contribute
to type I and type II IFN response following infection.
On the basis of the temporal IFN response associated with
CD11b+, Ly6G−, Ly6Chigh‑low cells, we next sought to determine
if they aﬀect viral replication. First, we investigated the viral titers
of reovirus within CD11b+, Ly6G−, Ly6Chigh‑low cells (intra-
cellular) as well as those present within the SOI (extracellular).
In congruence with the reoviral lambda protein expression pro-
ﬁle captured within the QTiPs data (Figure 4A), plaque assay-
based analysis for the intracellular and extracellular virus showed
the highest viral titers at 1 d.p.i. that steadily declined over the
course of 10 days (Figure 4B, C). These data demonstrated
the ability of inﬂammatory CD11b+, Ly6G−, Ly6Chigh‑low cells to
harbor reovirus in a time-dependent manner. In the context of
the proposed role for such myeloid cells as oncolytic virus
carriers,43−45 these ﬁndings bear clinical relevance.
Because the SOI contains a diverse mixture of immune cells,
we wanted to delineate whether the CD11b+, Ly6G−, Ly6Chigh‑low
cells speciﬁcally aﬀect viral persistence. For this purpose, we used
a well-documented CCR2 KO mouse model in which the
traﬃcking of inﬂammatory myeloid cells from the BM to the SOI
is defective.2 Importantly, this characteristic of impaired traﬃck-
ing of inﬂammatory myeloid cells in CCR2 KO mice is rou-
tinely used to identify the contribution of myeloid cells during
viral, bacterial, and parasitic infections.11,12,37,38 Thus, we ﬁrst
conducted comparative frequency/kinetic analysis of reovirus-
driven CD11b+, Ly6G−, Ly6Chigh‑low cells in wild-type (WT)
C57BL/6 versus CCR2KO mice and showed a near absence
of CD11b+, Ly6G−, Ly6Chigh‑low cell accumulation within the SOI
of CCR2KO mice (Figure 4D), conﬁrming the requirement of
CCR2 for the recruitment of CD11b+, Ly6G−, Ly6Chigh‑low cells
at the SOI. No signiﬁcant frequency/kinetics diﬀerences for
these cells were observed within the spleen and BM of WT vs
CCR2KO mice (Figure S-3A). Furthermore, the comparative
intracellular virus load analysis on total SOI-collected immune
cells illustrated signiﬁcantly higher titer of replication-competent
reovirus in CCR2KO mice (which contain a lower number of
CD11b+, Ly6G−, Ly6Chigh‑low cells) as compared to that of the
WT mice (Figure 4E) and suggested an antiviral role for
inﬂammatory myeloid cells. It should also be noted that these
inﬂammatory cells also contain the known antiviral mediators
including reactive oxygen species (ROS) and nitric oxide (NO),
especially at 1 d.p.i. (Figure 4F). Together, these analyses validate
the QTiPs-revealed role for CD11b+, Ly6G−, Ly6Chigh‑low cells in
viral clearance.
Virus-Driven CD11b+, Ly6G−, Ly6Chigh Cells Acquire
Enhanced Antigen Presentation Characteristics
A particularly interesting cluster of proteins, showed delayed
(7−10 d.p.i.) increased abundance in SOI- but not BM-isolated
CD11b+, Ly6G−, Ly6Chigh‑low cells (Figure 5A, cluster #4).
GO annotation of cluster #4 illustrated an increased peptidase
activity (MF) within these cells during the later stages of infec-
tion, which included antigen processing/presentation-associated
proteins, such asCathepsin B (CATB) andCathepsinD (CATD),
that are essential to drive an eﬀective adaptive immune response
(Figure 5B, C).46 GO annotation also revealed an over-repre-
sentation of MFs of the immune eﬀector process, response
to wounding (e.g., PERF and ARGI1), homeostatic process,
endocytosis, and major histocompatibility complex (MHC)-II
antigen processing/presentation (e.g., MRC1 and HG2A) in
SOI-isolated cells (Figure 5B, D). qRT-PCR-based validation of
many of these targets showed consistent temporal gene
expression patterns for genes Mrc1, Pepd, H2-ab1, Cd74, Tpp1,
and Lip1 (Figure S-3B). Together, the QTiPs suggested the
acquisition of antigen-presentation capabilities by inﬂammatory
CD11b+, Ly6G−, Ly6Chigh‑low cells late during infection.
To validate this hypothesis, we examined MHC-II surface
expression on CD11b+, Ly6G−, Ly6Chigh‑low cells during infec-
tion. Congruent with our proteomics data, these cells demon-
strated higher surface expression of MHC-II at 7−10 d.p.i.
compared to those at 3 and 5 d.p.i.; however, it was interesting to
note that these cells were initially recruited with elevated MHC-II
expression at 1 d.p.i. (Figure 5E). Finally, to demonstrate the
antigen presentation capacity, we monitored the ability of virus-
driven CD11b+, Ly6G−, Ly6Chigh‑low cells to present the immuno-
dominant epitope of ovalbumin (OVA; peptide SIINFEKL) in the
context ofMHC-I. Importantly, CD11b+, Ly6G−, Ly6Chigh‑low cells
showed the highest capacity to present SIINFEKL at 7 d.p.i.
(Figure 5F). Altogether, our data suggest that inﬂammatory
CD11b+, Ly6G−, Ly6Chigh‑low cells undergo a phenotypic and
functional transition to acquire enhanced antigen processing/
presentation abilities during the later stage of infection.
Metabolic Reprogramming Accompanies Inﬂammatory
CD11b+, Ly6G−, Ly6Chigh‑low Cell Transition/Diﬀerentiation
Because of the connection between distinct metabolic pathways
and myeloid cell functional capacities, and based on the QTiPs-
identiﬁed induction of proteins regulating metabolism (e.g.,
LDHA), we also assessed the metabolic proﬁles of transitory
CD11b+, Ly6G−, Ly6Chigh‑low cells. Metabolic-associated pro-
teins (indicated by BPs and cellular compartment GO annota-
tion analysis) were evident in cluster #5 with an increasing trend
from 1 to 10 d.p.i. in SOI-isolated cells (Figure S-4A−C).
We compared our QTiPs data set to the mouse MitoCarta2.0
data set34,35 to exclusively examine known mitochondrial pro-
teins. Using k-means clustering, we subdivided the total mitochon-
dria-associated proteomic data into various clusters (Mito-
clusters #1−10; Figure 6A and Figure S-5). GO annotation
analysis of Mito-clusters #1 and 2 showed an over-representation
of proteins involved in cellular response to ROS, the fatty acid
metabolic process, response to oxidative stress, and generation of
precursor metabolites and energy (Figure S-6A). KEGG pathway
analysis41,42 of Mito-clusters #1−2 showed an over-representa-
tion of fatty acid metabolism, oxidative phosphorylation, and the
citric acid cycle (Figure S-6A), and STRING network analysis47
further illustrated the interaction of these pathways among all
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metabolic pathway-associated proteins (shown in red) within
these clusters (Figure 6B). Individual protein proﬁle analysis
from Mito-clusters #1 and 2 of the citrate acid cycle, fatty
acid metabolism, and oxidative phosphorylation revealed a
general increasing trend from 1 to 10 d.p.i. (Figure 6C). These
analyses highlight the metabolic reprogramming of inﬂam-
matory CD11b+, Ly6G−, Ly6Chigh‑low cells following viral infec-
tion.
Because the proteomic data suggested a metabolic switch in
SOI-isolated CD11b+, Ly6G−, Ly6Chigh‑low cells, especially at
7−10 d.p.i., we examined time-dependent cellular bioenergetics
(mitochondrial respiration and glycolysis) (Figure 6D and
Figure S-6B) in isolated CD11b+, Ly6G−, Ly6Chigh‑low cells.
As shown in Figure 6E and Figure S-6C, SOI isolated cells
displayed the highest basal oxygen consumption rate (OCR), ATP
produc-
Figure 6.Temporal metabolic reprogramming of inﬂammatory CD11b+, Ly6G−, Ly6Chigh‑low cells. (A) Comparison of the total proteomic data set with
MitoCarta2.0 data set to generate clusters via k-means clustering and Euclidean distance analysis. Selected 2 of 10 clusters are illustrated via heat map
with indicated protein IDs. (B) String network analysis of Mito-cluster #1 and 2 illustrating metabolic pathway-associated proteins in red, and encircled
are the identiﬁed proteins associated with the indicated KEGGpathway and their interactions. (C) Individual protein proﬁles (also highlighted in red in A)
pertaining to the indicated KEGG pathways. (D) OCR of isolated cells for each collection point. Basal OCR and ECAR graphically represented
(E) and summarized for the spare respiratory capacity (%) (F) and glycolytic reserve (%) (G). Graphs in D−G are data represented as mean± SEM and
collected from n = 1−4 each with a pooled population from 5 to 10 mice. One-way ANOVA with Bonferroni post-test (F−H) with 95% conﬁdence
interval were used for statistical analysis, and p-values of <0.05 were considered signiﬁcant. Asterisks were used to signify p-values as *p ≤ 0.05,
**p ≤ 0.01, and ***p ≤ 0.001.
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tion (Figure S-6D), and proton leak (Figure S-6E) at 7 d.p.i.,
suggesting higher bioenergetic demand at 7 d.p.i.. Concur-
rently, basal extracellular acidiﬁcation rate (ECAR) (Figure 6E
and Figure S-6F) of isolated CD11b+, Ly6G−, Ly6Chigh‑low cells
were also greatest at 7−10 d.p.i. Importantly, the opposing trend
was observed with spare respiratory capacity (Figure 6F), maximal
OCR (Figure S-6G), and glycolytic reserve (Figure 6G and
Figure S-6H), indicating that these cells utilize glycolysis close to
their theoretical maximum at 7−10 d.p.i. These data show that
inﬂammatory CD11b+, Ly6G−, Ly6Chigh‑low cells undergo
metabolic reprogramming at the SOI and increase both glycolytic
and respiratory capacities during the later stages of infection.
Virus-Driven CD11b+, Ly6G−, Ly6Chigh Cells Acquire M2-like
Macrophage Characteristics
It has been hypothesized that immature myeloid cells give rise to
antigen-presenting cells (APCs), especially those of monocytic
lineage.48 Our data suggest that the virus-driven CD11b+, Ly6G−,
Ly6Chigh‑low cells undergo temporal transformation and acquire
molecular signatures of APCs. Hence, we next investigated
whether these myeloid cells diﬀerentiate into any speciﬁc sub-
type of the APCs. The QTiPs data (Figure 7A) identiﬁed an
increasing trend for proteins (CCL24, ARG-1, Alox15, Stab1,
and TGF-β) characteristic of M2 macrophages between 1 and
10 d.p.i. in SOI-isolatedmyeloid cells. In contrast,M1-macrophage-
Figure 7. Late-stage reovirus-driven CD11b+, Ly6G−, Ly6C+ cells acquire M2-like macrophage characteristics. (A, B) Individual protein proﬁles of
M2- and M1-macrophage-associated proteins, respectively, from total proteomic data set shown in Figure 1B. Flow cytometry analysis of CD206
(C) and CCR2 (D) surface expression on CD11b+, Ly6G−, Ly6Chigh‑low cells. qRT-PCR analysis of isolated CD11b+, Ly6G−, Ly6Chigh‑low cells for Irf4
(E), Irf5 (F), Ccl17 (G), and M1-macrophage-associated genes (H). Flow cytometry analysis for CD206 (C) and CCR2 (D) represents mean ± SEM
with n = 3−5 mice. qRT-PCR analysis in (E, F) are from a pooled population of 5−10 mice, n = 2, ran in duplicate, normalized to GAPDH, and
compared to 1 d.p.i. BM sample (indicated by the dotted line) to obtain the fold change. One-way ANOVA with Bonferroni post-test (C−H) with 95%
conﬁdence interval was used for statistical analysis, and p-values of <0.05 were considered signiﬁcant. Asterisks were used to signify p-values as *p≤ 0.05,
**p ≤ 0.01, and ***p ≤ 0.001.
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associated proteins (IRF5,MMP9, and IRF1) showed the oppos-
ing trend (Figure 7B). In support of this, ﬂow cytometry anal-
ysis of inﬂammatory CD11b+, Ly6G−, Ly6Chigh‑low cells further
identiﬁed contrasting kinetics for the surface expression of M2
macrophage marker CD206 (increased over time; Figure 7C)
and M1 macrophage marker CCR2 (decreased over time;
Figure 7D). In line with our metabolic bioenergetics, these
results reveal the transition of inﬂammatory CD11b+, Ly6G−,
Ly6Chigh‑low cells into M2-like macrophages around 7−10 d.p.i.
To further strengthen our hypothesis that the inﬂammatory
CD11b+, Ly6G−, Ly6Chigh‑low cells acquire M2-like macrophage
characteristics, we performed qRT-PCR on SOI- and BM-isolated
CD11b+, Ly6G−, Ly6Chigh‑low cells. First, we analyzed the expres-
sion of key transcription factors Irf4 and Irf5 known to be
involved in M2 vs M1 macrophage polarization, respec-
tively.49−51 As shown in Figure 7E and F, SOI-isolated myeloid
cells showed contrasting proﬁles of Irf4 and Irf5 between 1 and
10 d.p.i.; the levels of M2-macrophage transcription factor Irf4
increased over time, whereas Irf5 decreased over time. Further-
more, using a list of M2 and M1 macrophage markers,52,53 we
showed thatM2-associated markerCcl17 followed a similar trend
as Irf4 (Figure 7G), whereas additional M2-associated genes
(Ym1, Cd206, and Il4) displayed mostly nonsigniﬁcant changes
(Figure S-7A). Importantly, the expression of M1-associated
markers (Cd86, Il-1β, Cd68, Socs1, Tnfα, and Ifnγ) showed an
opposing trend throughout infection with decreasing expres-
sion from 1 to 10 d.p.i. (Figure 7H). Analysis of M2- and
M1-associated genes in the BM-isolated cells showed little sig-
niﬁcant variation (Figure S-7B and C, respectively). These
results, in combination with QTiPs analysis, conclusively demon-
strate that the virus-driven CD11b+, Ly6G−, Ly6Chigh‑low cells
undergo phenotypic and functional transition at the SOI and
acquire the characteristics of M2 macrophages.
■ DISCUSSION
Myeloid cells and their descendants, including monocytes,
dendritic cells, macrophages, or myeloid-derived suppressor cells
(MDSCs), play pivotal roles in both innate and adaptive
immunity during infections. With regard to viral infections,
newly recruited Ly6Chigh monocytes have been implicated in viral
clearance following infection with West Nile virus, vaccinia virus,
murine cytomegalovirus, and inﬂuenza virus.54−56 These studies
demonstrate that viral-driven myeloid cells readily interact with
other innate (NK cells) and adaptive cells (virus-speciﬁc CD8+
T cells)11,56 and contribute toward viral clearance as well as disease
pathology through direct or indirect mechanisms. For instance,
inﬂammatory myeloid cells recruited following mouse hepa-
titis virus (MHV) contribute toward virus clearance through a
CCR2-dependent mechanism.57 Furthermore, inﬂuenza-medi-
ated CD11b+, Ly6Chigh cell recruitment is a major contributor to
excessive collateral damage within the lungs, and the absence of
such recruitment compromises viral clearance and decreases the
CD8+ T cell frequency.11 In congruence with these reports, our
data demonstrates that the recruitment of reovirus-driven
CD11b+, Ly6G−, Ly6Chigh inﬂammatory cells is CCR2-depend-
ent (Figure 4D) and that their presence at the SOI positively
correlates with viral clearance (Figure 4E). Interestingly, at the
SOI, intracellular virus be found within the cells with and without
the CD11b+, Ly6G−, Ly6Chigh phenotype (Figure 4E), suggest-
ing the involvement of other immune cells in antiviral immune
reactivities. Thus, it could be concluded that virus-driven CD11b+,
Ly6G−, Ly6Chigh inﬂammatory cells, in combination with other
immune constituents, contribute toward virus clearance.
Here, we provide the ﬁrst comprehensive temporospatial quan-
titative proteomic analysis of inﬂammatory CD11b+, Ly6G−,
Ly6Chigh‑low cells directly isolated from their in situ microenviron-
ment. Notably, our QTiPs approach accounts for host environ-
mental factors, such as cytokines, metabolic changes, and immune
inﬁltrating/resident cells, at the SOI. In combination with
detailed biological validation, the QTiPs data show that reovirus-
driven CD11b+, Ly6G−, Ly6Chigh‑low cells have diﬀerential roles
throughout the course of infection: newly recruited CD11b+,
Ly6G−, Ly6Chigh cells mount a robust immune response and aid
in viral clearance during the early phase of infection (1−5 d.p.i.),
whereas during late phase infection (7 and 10 d.p.i.), these cells
undergo a metabolic shift, acquire enhanced antigen-presenta-
tion capacity, and achieve M2-like macrophage characteristics.
Quantitative multiplexed proteomic approaches (e.g., label-
free, tags, or stable isotope labeling) represent an unbiased
strategy to observe global proteomic changes and answer key
biological questions. With respect to immunological studies,
label-free quantitation has been the predominant means to
investigate proteomic discrepancies of ex vivo expanded/
cultured or transformed cell lines (e.g., cytotoxic T lympho-
cytes,58 dendritic cells, and/or macrophages59−61), and primary-
isolated cells such as dendritic cell subsets,62 MDSCs,63 and
human T cells.64 Unlike such label-free approaches, TMT
reagents now facilitate simultaneous analysis of 10 proteomes.
Employing TMT in our QTiPs approach enabled accurate and
deep proteomic coverage of in vivo proteomic proﬁles of isolated
CD11b+, Ly6G−, Ly6Chigh‑low cells. The temporal nature of the
data set revealed a secondary phase of antiviral/wound damage
response at 5 d.p.i. indicative of increased type I and II IFN-
associated proteins (e.g., IFI5A, IRF5, IRG1, and Q9DCE9, an
IFN-γ-induced GTPase). IFI5A in particular has been shown to
be a transcriptional regulatory factor induced during myeloid cell
development65 and may have implications in CD11b+, Ly6G−,
Ly6Chigh‑low cell diﬀerentiation at 5−10 d.p.i. Furthermore, late
stage variations illustrated in clusters #4 and 5 orMito-clusters #1
and 2 correlate with increased antigen presentation/processing
and metabolic shift, respectively. Such temporal ﬂuctuations in
the proteomes highlight the advantages of utilizing an approach
that monitors the in vivo dynamics of an immune cell population.
Our QTiPs approach provides a global, timely, and in depth
platform facilitating the capture of immune cell transitions while
accounting for the interplay between cytokines and immune cells
throughout the course of infection.
Considering the current contentious nomenclature and
phenotypic categorization around myeloid cells and its derivative
subpopulations,52 we identiﬁed virus-driven murine myeloid
cells simply by their factual phenotype (based on CD11b, Ly6G,
and Ly6C surface expression). To this end, we viewed these
myeloid cells as a newly recruited cell population at the SOI and
then analyzed their transition into existing paradigmal sub-
populations in terms of surface marker, gene expression, pro-
tein, and metabolic proﬁles. Our temporal analysis reveals
that SOI-associated CD11b+, Ly6G−, Ly6Chigh cells undergo a
time-dependent decrease in Ly6C expression and display
increased MHC-II expression and wound healing characteristics
at 7−10 d.p.i., suggesting maturation/diﬀerentiation during the
later stages of infection. Upon further dissection, we observed
thatM2-macrophage-associated proteins and transcripts increase
at 7−10 d.p.i. as opposed to pro-inﬂammatory/M1-macrophage-
associated markers that are upregulated during the early stages of
infection. Similar to myeloid cells, there is a growing appreciation
for the plasticity of the distinction between M1- vs M2-like
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macrophages. It is now acknowledged that macrophages rather
demonstrate a spectrum of phenotypic, functional, and phys-
iological features of M1 and M2 classes and thus often display
these features in a context-dependent manner. It should be noted
that many of the M1- or M2-associated features have been
originally discovered in the context of the macrophages that were
generated using deﬁned in vitro growth conditions, such as
through the supplementation of GM-CSF or M-CSF. Thus, it
is possible that cells diﬀerentiated in the context of the complex
in vivo milieu hosting a myriad of soluble and cellular interacting
partners bear a diﬀerential pattern of M1 and M2 markers that
is observed with the in vitro-generated macrophages. In our
analysis, virus-driven CD11b+, Ly6G−, Ly6Chigh cells show
several M2-associated markers during the later phases of
infection; however, at the same, these cells failed to show any
congruent trends with of Il4, Ym1, and Cd206 gene expression
that have been described to be associated with the M2
phenotype. On the basis of these ﬁndings, we surmise that the
macrophages generated in a complex in vivo microenviron-
ment diﬀer from those generated in vitro using deﬁned growth
conditions and should be considered as such with a special
consideration for their microenvironmental context.
The metabolic signature of myeloid cells, particularly macro-
phages, is a major hallmark to distinguish contrasting M1 vs M2
macrophage phenotypes.66 In comparison to this existing par-
adigm and our own experiments with ex vivo-generated/cultured
M1- and M2-like macrophages (Figure S-7D, E),66 we observed
that CD11b+, Ly6G−, Ly6Chigh‑low cells became more metabol-
ically active during the later stages of infection, as indicated by
increasing basal OCR and basal ECAR (Figure 6D, E). Such a
metabolic shift could be indicative of the necessity to require
energy for newly acquired endocytic, antigen presentation, and/
or M2-like functionality. In the context of currently reported
metabolic proﬁles assigned to M1- (low basal OCR, high basal
ECAR, and low spare respiratory capacity) and M2- (high OCR,
low basal ECAR, and high spare respiratory capacity) macro-
phages, the infection-driven CD11b+, Ly6G−, Ly6Chigh‑low cells
demonstrate a dynamic metabolic signature in the transition
between M1- and M2-like macrophages in line with the pro-
teomic signature elucidated through QTiPs. This analysis fur-
ther conﬁrms the highly plastic nature of the myeloid cell−
macrophage transition and, in line with the recent evidence67,68
speciﬁcally using lipopolysaccharide/TLR4 stimulation versus
IL-4-stimulated BM-derived macrophages, further supports the
hypothesis that in vitro-generated macrophages do not com-
pletely recapitulate all metabolic and functional characteristics of
in vivo-isolated or human cells.
In conclusion, QTiPs analysis comprehensively captures the
temporospatial transition of inﬂammatory CD11b+, Ly6G−,
Ly6Chigh‑low cells following reovirus infection. These data contain
a plethora of information on native, as well as infection-driven,
myeloid cells that reside in the BM or at the SOI and are a
resource for future hypothesis testing with regard to myeloid-
speciﬁc diﬀerentiation, antiviral response, and metabolic altera-
tion. The data also have implications for the therapeutic manage-
ment of myeloid cells in the context of antiviral immune
responses, vaccine development, cancer immunotherapies, and
especially oncolytic virus therapies, which are known to drive
myeloid cell recruitment to the tumor microenvironment
following administration.26 Our data also demonstrate that the
QTiPs approach can be applied further to precisely capture
the complex, dynamic, and temporal nature of other types of
immune cells collected from their in situ microenvironment.
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